Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
Caribou Biosciences reported robust long-term efficacy for vispa-cel in second-line large B cell lymphoma, achieving an 82% overall response rate and 67% complete response rate in the pivotal optimized subgroup. The therapy demonstrated a median progression-free survival of 17.1 months with a generally well-tolerated safety profile, including no cases of graft-versus-host disease in the 27-patient subgroup.
Key figures
- Drug Name
- vispa-cel
- Phase Of Trial
- Phase 1
- Orr
- 82%
- Dose
- 80 million CAR-T cells
- Cr rate
- 67%
- Median pfs
- 17.1 months
- Patients treated total trial
- 85
- Patients treated pivotal subgroup
- 27
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.